COVID-19 Tests

Atomo’s platform is a natural fit for a fast, accurate point of care diagnostic for COVID-19. Atomo offers an antigen test for the qualitative detection of nucleocapsid protein antigens specific to the SARS-CoV-2 virus, as well as an antibody test to indicate if a user has an antibody response to the virus.

COVID-19 Rapid Antigen Test

Sold in Australia & New Zealand
A fast, accurate point of care COVID-19 antigen test for the qualitative detection of nucleocapsid protein antigens specific to the SARS-CoV-2 virus.

COVID-19 Rapid Antibody Test

Sold in Australia
Branded & Distributed by NG Biotech for sale in Europe
A fast, accurate point of care COVID-19 antibody test to indicate exposure to the virus on Atomo’s integrated easy to use platform.

Finished rapid test products are commercialized under Atomo's own brand or under private labels via partners and regional distributors. We hold regulatory approvals including CE Mark in the EU/ UK, Australian TGA, and the World Health Organization with FDA approvals pending.

Develop Future Tests With Us

Atomo’s unique technology presents an opportunity to improve existing products on the market with superior usability. Our integrated platforms can help users easily perform the tests on their own and improve performance, speed and reliability in a professional clinical setting.

We welcome dialogue with forward-thinking diagnostic partners who would like to explore co-developing tests for infectious diseases, allergy sensitivities, women’s health, men’s health, sexual health, heart health and other applications.

Re-imagining diagnostics.